Browse NFKB1

Summary
SymbolNFKB1
Namenuclear factor of kappa light polypeptide gene enhancer in B-cells 1
Aliases KBF1; NFKB-p50; NF-kappaB; NFkappaB; NF-kB1; EBP-1; NF-kappa-B; NFKB-p105; DNA binding factor KBF1; DNA-bind ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm. Note=Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).
Domain PF00023 Ankyrin repeat
PF12796 Ankyrin repeats (3 copies)
PF00531 Death domain
PF16179 Rel homology dimerisation domain
PF00554 Rel homology DNA-binding domain
Function

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.

> Gene Ontology
 
Biological Process GO:0000271 polysaccharide biosynthetic process
GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0002218 activation of innate immune response
GO:0002220 innate immune response activating cell surface receptor signaling pathway
GO:0002223 stimulatory C-type lectin receptor signaling pathway
GO:0002237 response to molecule of bacterial origin
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0005976 polysaccharide metabolic process
GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006066 alcohol metabolic process
GO:0006109 regulation of carbohydrate metabolic process
GO:0006694 steroid biosynthetic process
GO:0006766 vitamin metabolic process
GO:0006775 fat-soluble vitamin metabolic process
GO:0006869 lipid transport
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0008202 steroid metabolic process
GO:0009110 vitamin biosynthetic process
GO:0009612 response to mechanical stimulus
GO:0010586 miRNA metabolic process
GO:0010742 macrophage derived foam cell differentiation
GO:0010743 regulation of macrophage derived foam cell differentiation
GO:0010744 positive regulation of macrophage derived foam cell differentiation
GO:0010876 lipid localization
GO:0010883 regulation of lipid storage
GO:0010884 positive regulation of lipid storage
GO:0010894 negative regulation of steroid biosynthetic process
GO:0010956 negative regulation of calcidiol 1-monooxygenase activity
GO:0010957 negative regulation of vitamin D biosynthetic process
GO:0015850 organic hydroxy compound transport
GO:0015918 sterol transport
GO:0016051 carbohydrate biosynthetic process
GO:0016055 Wnt signaling pathway
GO:0019216 regulation of lipid metabolic process
GO:0019218 regulation of steroid metabolic process
GO:0019915 lipid storage
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030203 glycosaminoglycan metabolic process
GO:0030212 hyaluronan metabolic process
GO:0030213 hyaluronan biosynthetic process
GO:0030301 cholesterol transport
GO:0030656 regulation of vitamin metabolic process
GO:0031098 stress-activated protein kinase signaling cascade
GO:0031293 membrane protein intracellular domain proteolysis
GO:0031348 negative regulation of defense response
GO:0031349 positive regulation of defense response
GO:0032102 negative regulation of response to external stimulus
GO:0032368 regulation of lipid transport
GO:0032369 negative regulation of lipid transport
GO:0032371 regulation of sterol transport
GO:0032372 negative regulation of sterol transport
GO:0032374 regulation of cholesterol transport
GO:0032375 negative regulation of cholesterol transport
GO:0032479 regulation of type I interferon production
GO:0032481 positive regulation of type I interferon production
GO:0032496 response to lipopolysaccharide
GO:0032606 type I interferon production
GO:0032615 interleukin-12 production
GO:0032655 regulation of interleukin-12 production
GO:0032695 negative regulation of interleukin-12 production
GO:0032768 regulation of monooxygenase activity
GO:0032769 negative regulation of monooxygenase activity
GO:0032881 regulation of polysaccharide metabolic process
GO:0032885 regulation of polysaccharide biosynthetic process
GO:0033619 membrane protein proteolysis
GO:0035094 response to nicotine
GO:0035994 response to muscle stretch
GO:0038061 NIK/NF-kappaB signaling
GO:0038093 Fc receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0042035 regulation of cytokine biosynthetic process
GO:0042036 negative regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042090 interleukin-12 biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042359 vitamin D metabolic process
GO:0042362 fat-soluble vitamin biosynthetic process
GO:0042368 vitamin D biosynthetic process
GO:0043255 regulation of carbohydrate biosynthetic process
GO:0043279 response to alkaloid
GO:0043331 response to dsRNA
GO:0043434 response to peptide hormone
GO:0044283 small molecule biosynthetic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0045075 regulation of interleukin-12 biosynthetic process
GO:0045083 negative regulation of interleukin-12 biosynthetic process
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045833 negative regulation of lipid metabolic process
GO:0045913 positive regulation of carbohydrate metabolic process
GO:0045939 negative regulation of steroid metabolic process
GO:0046137 negative regulation of vitamin metabolic process
GO:0046165 alcohol biosynthetic process
GO:0046890 regulation of lipid biosynthetic process
GO:0050727 regulation of inflammatory response
GO:0050728 negative regulation of inflammatory response
GO:0050810 regulation of steroid biosynthetic process
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0051051 negative regulation of transport
GO:0051055 negative regulation of lipid biosynthetic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051235 maintenance of location
GO:0051341 regulation of oxidoreductase activity
GO:0051354 negative regulation of oxidoreductase activity
GO:0051403 stress-activated MAPK cascade
GO:0060070 canonical Wnt signaling pathway
GO:0060556 regulation of vitamin D biosynthetic process
GO:0060558 regulation of calcidiol 1-monooxygenase activity
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0070555 response to interleukin-1
GO:0070741 response to interleukin-6
GO:0071214 cellular response to abiotic stimulus
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071260 cellular response to mechanical stimulus
GO:0071312 cellular response to alkaloid
GO:0071316 cellular response to nicotine
GO:0071347 cellular response to interleukin-1
GO:0071354 cellular response to interleukin-6
GO:0071359 cellular response to dsRNA
GO:0071375 cellular response to peptide hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071496 cellular response to external stimulus
GO:0090077 foam cell differentiation
GO:0090263 positive regulation of canonical Wnt signaling pathway
GO:0198738 cell-cell signaling by wnt
GO:1900125 regulation of hyaluronan biosynthetic process
GO:1900127 positive regulation of hyaluronan biosynthetic process
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1902930 regulation of alcohol biosynthetic process
GO:1902931 negative regulation of alcohol biosynthetic process
GO:1903510 mucopolysaccharide metabolic process
GO:2000628 regulation of miRNA metabolic process
GO:2000630 positive regulation of miRNA metabolic process
Molecular Function GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding
GO:0001158 enhancer sequence-specific DNA binding
GO:0001205 transcriptional activator activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0008134 transcription factor binding
GO:0035326 enhancer binding
GO:0042805 actinin binding
GO:0046982 protein heterodimerization activity
Cellular Component GO:0033256 I-kappaB/NF-kappaB complex
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04014 Ras signaling pathway
hsa04024 cAMP signaling pathway
hsa04062 Chemokine signaling pathway
hsa04064 NF-kappa B signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04071 Sphingolipid signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04210 Apoptosis
hsa04380 Osteoclast differentiation
hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04622 RIG-I-like receptor signaling pathway
hsa04623 Cytosolic DNA-sensing pathway
hsa04660 T cell receptor signaling pathway
hsa04662 B cell receptor signaling pathway
hsa04668 TNF signaling pathway
hsa04722 Neurotrophin signaling pathway
hsa04917 Prolactin signaling pathway
hsa04920 Adipocytokine signaling pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-1169091: Activation of NF-kappaB in B cells
R-HSA-1280218: Adaptive Immune System
R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5621575: CD209 (DC-SIGN) signaling
R-HSA-5607764: CLEC7A (Dectin-1) signaling
R-HSA-5660668: CLEC7A/inflammasome pathway
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1834949: Cytosolic sensors of pathogen-associated DNA
R-HSA-3134963: DEx/H-box helicases activate type I IFN and inflammatory cytokines production
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5602358: Diseases associated with the TLR signaling cascade
R-HSA-5260271: Diseases of Immune System
R-HSA-202424: Downstream TCR signaling
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2871837: FCERI mediated NF-kB activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-5603027: IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
R-HSA-5603029: IkBA variant leads to EDA-ID
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-448706: Interleukin-1 processing
R-HSA-446652: Interleukin-1 signaling
R-HSA-450294: MAP kinase activation in TLR cascade
R-HSA-5684264: MAP3K8 (TPL2)-dependent MAPK1/3 activation
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-209560: NF-kB is activated and signals survival
R-HSA-6798695: Neutrophil degranulation
R-HSA-3214841: PKMTs methylate histone lysines
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
R-HSA-1810476: RIP-mediated NFkB activation via ZBP1
R-HSA-193692: Regulated proteolysis of p75NTR
R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-445989: TAK1 activates NFkB by phosphorylation and activation of IKKs complex
R-HSA-202403: TCR signaling
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-933542: TRAF6 mediated NF-kB activation
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
R-HSA-1606322: ZBP1(DAI) mediated induction of type I IFNs
R-HSA-193704: p75 NTR receptor-mediated signalling
R-HSA-193639: p75NTR signals via NF-kB
Summary
SymbolNFKB1
Namenuclear factor of kappa light polypeptide gene enhancer in B-cells 1
Aliases KBF1; NFKB-p50; NF-kappaB; NFkappaB; NF-kB1; EBP-1; NF-kappa-B; NFKB-p105; DNA binding factor KBF1; DNA-bind ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NFKB1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between NFKB1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26573793Ovarian CarcinomaInhibit immunity (T cell function)In summary, we found that chemotherapy induces local immune suppression in ovarian cancer through NF-κB-mediated PD-L1 upregulation.
26567141Ovarian CarcinomaPromote immunityPD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB.
26903482MelanomaPromote immunity (T cell function)We hypothesized that forcing T cell-intrinsic NF-κB activation might break this cycle and induce tumor elimination. NF-κB was activated in T cells by inducing the expression of a constitutively active form of the upstream activator IκB kinase β (IKKβ). T cell-restricted constitutively active IKKβ augmented the frequency of functional tumor-specific CD8(+) T cells and improved tumor control.
22474024Colon CarcinomaInhibit immunity (T cell function)Experiments using small interfering RNA and a chemical inhibitor of FKBP51 revealed that FKBP51 contributes to the regulation of the suppressive function of MDSCs by increasing inducible NO synthase, arginase-1, and reactive oxygen species levels and enhancing NF-κB activity.
19299748Plasma cell myelomaPromote immunity (B cell function)In conclusion, our results show that TLR3 ligand induces NF-kappaB pathway activation in MM and support a switching function of type I IFN in the functional outcome of TLR3 triggering in tumor cells.
21278794Breast CarcinomaPromote immunitySecretion of pro-inflammatory cytokines by the senescent cells, particularly TNF-α and IFN-γ, mediates Fas upregulation. Indeed, treatment of proliferating cancer cell lines with TNF-α and IFN-γ, upregulates Fas expression, while blocking TNF-α and IFN-γ by using neutralizing antibodies, decreases Fas expression in senescent cells. We also demonstrate that NF-κB has a central role in controlling the senescence-associated secretory phenotype (SASP) by the premature senescent cells, and that TNF-α and IFN-γ, transcriptionally controlled by NF-κB, are the main mediators of Fas upregulation. Our data suggest the existence of an NF-κB-dependent autocrine loop, mediated by TNF-α and IFN-γ, responsible for expression of Fas on the surface of senescent cells, and for their killing.
19671844Hodgkin LymphomaInhibit immunityHeat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
23635779Lung Carcinoma; Lung AdenocarcinomaPromote immunity (infiltration)Using a global RNA expression microarray, we demonstrated that NF-κB enhanced expression of several T cell chemokines, including Ccl2, and decreased CCL2 expression was associated with enhanced tumor growth in a mouse lung cancer model. In patient tumor samples, overall lung tumor NF-κB activity was strongly associated with T cell infiltration but not with cancer cell proliferation.
17210719SacromaInhibit immunityTumor-induced oxidative stress increased cytosolic IkappaBalpha retention and inhibited NF-kappaB nuclear translocation in thymic T cells. These NF-kappaB-perturbed cells became vulnerable to tumor-secreted tumor necrosis factor (TNF)-alpha (TNF-alpha)-mediated apoptosis through the activation of TNF receptor-associated protein death domain-associated Fas-associated protein death domain and caspase-8. When T cells were overexpressed with NF-kappaB, the cells became resistant to tumor-induced apoptosis.
25024217melanomaPromote immunity (T cell function); essential for immunotherapyThe transcription factor NF-κB is central to inflammatory signaling and activation of innate and adaptive immune responses. In contrast, relief from the A20 brake in NF-κB activation in adoptively transferred antitumor CD8 T cells led to improved control of melanoma growth. Moreover, systemic delivery of NPsiCDK1 is able to suprress tumor growth in mice bearing SUM149 and BT549 xenograft and cause no systemic toxcity or activate the innate immune response, suggesting the therapeutic promise with such nanoparticles carrying siCDK1 for c-Myc overexpressed triple negative breast cancer.
24975576adenocarcinomaInhibit immunityBoth activation of the pathway and termination of the NF-κB response are tightly regulated events, which is essential to prevent exacerbated inflammatory responses.
24867687Ovarian CarcinomaInhibit immunity (T cell function); immunotherapy targetNF-κB is involved in the immunosuppression induced by human EOC, and its inhibitor may restore antitumour immune responses, indicating that NF-κB is an attractive target for EOC treatment.
29672044Colorectal CarcinomaInhibit immunity (T cell function); immunotherapy targetWe found that NF-κB and AP-1 were the critical transcription factors for TNF-α-induced IL-8 expression.
27923823Nasopharyngeal CarcinomaInhibit immunityNegative feedback inhibited the transcription of NF-κB, which is important for activating IRF-1 expression.
15986139MelanomaInhibit immunityNuclear Factor-kappa B (NF-kappa B) is an inducible transcription factor that regulates the expression of many genes involved in the immune response.
28891811Pancreatic CarcinomaInhibit immunityNF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor development. Mechanistically, we found that GDF-15 suppresses macrophage activity by inhibiting TGF-β-activated kinase (TAK1) signaling to NF-κB, thereby blocking synthesis of TNF and NO.
24379122Breast CarcinomaInhibit immunityFurthermore, tmTNF-α caused p38 phosphorylation and NF-κB activation, whereas inhibition of NF-κB or p38 with an inhibitor pyrrolidine dithiocarbamate or SB203580 abrogated tmTNF-α-mediated increased suppression of lymphocyte proliferation by MDSCs.
25242680renal cell carcinomaInhibit immunity (T cell function)Most interestingly, our results suggest that the nuclear factor-kappa B signaling pathway might be involved in the impairment of immunological responsiveness and the observed TH-2 deviation
25100611melanomaPromote immunityThus, we could show that activation of NF-κB is indeed sufficient to enable the DCs to produce IL-12 and to repetitively stimulate CTLs
25063873Breast CarcinomaInhibit immunityThese results demonstrate a STAT3/NF-κB/IDO pathway in breast cancer-derived MDSCs, which provides insight into understanding immunosuppressive mechanisms of MDSCs in breast cancer. We have identified a poorly differentiated MDSC subset in breast cancer-suppressing T cell function through STAT3-dependent IDO upregulation
Summary
SymbolNFKB1
Namenuclear factor of kappa light polypeptide gene enhancer in B-cells 1
Aliases KBF1; NFKB-p50; NF-kappaB; NFkappaB; NF-kB1; EBP-1; NF-kappa-B; NFKB-p105; DNA binding factor KBF1; DNA-bind ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NFKB1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNFKB1
Namenuclear factor of kappa light polypeptide gene enhancer in B-cells 1
Aliases KBF1; NFKB-p50; NF-kappaB; NFkappaB; NF-kB1; EBP-1; NF-kappa-B; NFKB-p105; DNA binding factor KBF1; DNA-bind ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NFKB1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1850.462
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2210.906
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1660.895
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3210.273
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6540.771
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.10.972
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.090.814
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0020.999
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2080.908
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8120.534
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4140.467
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1670.00821
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NFKB1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277304.1-4.10.561
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275905.1-5.10.549
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNFKB1
Namenuclear factor of kappa light polypeptide gene enhancer in B-cells 1
Aliases KBF1; NFKB-p50; NF-kappaB; NFkappaB; NF-kB1; EBP-1; NF-kappa-B; NFKB-p105; DNA binding factor KBF1; DNA-bind ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NFKB1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNFKB1
Namenuclear factor of kappa light polypeptide gene enhancer in B-cells 1
Aliases KBF1; NFKB-p50; NF-kappaB; NFkappaB; NF-kB1; EBP-1; NF-kappa-B; NFKB-p105; DNA binding factor KBF1; DNA-bind ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NFKB1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NFKB1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNFKB1
Namenuclear factor of kappa light polypeptide gene enhancer in B-cells 1
Aliases KBF1; NFKB-p50; NF-kappaB; NFkappaB; NF-kB1; EBP-1; NF-kappa-B; NFKB-p105; DNA binding factor KBF1; DNA-bind ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NFKB1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNFKB1
Namenuclear factor of kappa light polypeptide gene enhancer in B-cells 1
Aliases KBF1; NFKB-p50; NF-kappaB; NFkappaB; NF-kB1; EBP-1; NF-kappa-B; NFKB-p105; DNA binding factor KBF1; DNA-bind ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NFKB1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNFKB1
Namenuclear factor of kappa light polypeptide gene enhancer in B-cells 1
Aliases KBF1; NFKB-p50; NF-kappaB; NFkappaB; NF-kB1; EBP-1; NF-kappa-B; NFKB-p105; DNA binding factor KBF1; DNA-bind ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NFKB1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNFKB1
Namenuclear factor of kappa light polypeptide gene enhancer in B-cells 1
Aliases KBF1; NFKB-p50; NF-kappaB; NFkappaB; NF-kB1; EBP-1; NF-kappa-B; NFKB-p105; DNA binding factor KBF1; DNA-bind ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NFKB1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting NFKB1.
ID Name Drug Type Targets #Targets
DB00945Acetylsalicylic acidSmall MoleculeAKR1C1, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, ......18
DB01041ThalidomideSmall MoleculeCRBN, FGFR2, NFKB1, ORM1, ORM2, PTGS2, TNF7
DB01411PranlukastSmall MoleculeCYSLTR1, IL5, MUC2, NFKB1, RNASE3, TNF6
DB05212HE3286Small MoleculeNFKB1, NFKB22
DB05451P54Small MoleculeNFKB1, NFKB22
DB05464NOX-700Small MoleculeNFKB1, NFKB22
DB05471SGN-30BiotechNFKB1, NFKB22
DB05487CustirsenSmall MoleculeESR1, NFKB1, NFKB23
DB05767AndrographolideSmall MoleculeIL1B, IL6, NFKB1, NFKB2, TNF5
DB08814TriflusalSmall MoleculeNFKB1, NOS2, PDE10A, PTGS14